Literature DB >> 15879622

Surgical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.

Florian Loehe1, Rolf J Schauer.   

Abstract

Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are progressive cholestatic liver diseases of supposed auto-immune etiology. The clinical course is unpredictable and, in many patients, leads to end-stage liver disease or a poor quality of life. Conservative therapy only has a limited effect on the natural history, but orthotopic liver transplantation(OLT) offers a definitive therapeutic option. Retrospective analysis was performed for 38 patients with PBC and 17 patients with PSC who underwent OLT between January 1986 and June 2003 at our institution. Median followup after OLT was 72 mo.Cumulative survival at 5 yr post-OLT was 84% in the PBC group and 73% in the PSC group. Compared with OLT for other benign diseases, actuarial survival rates at 5 and 10 yr post-OLT were significantly better for patients with PBC, whereas there was no difference in survival after OLT for patients with PSC. Survival rate at 5 yr post-OLT was significantly increased for patients with PBC who had a Child-Pugh B liver cirrhosis (93%) compared with those who had Child-Pugh C cirrhosis (60%). Retransplantation rate was 18.2% (resulting from biliary complications in three cases). Surgical techniques had no effect on outcome after OLT in both groups. We concluded that liver transplantation represents a safe and beneficial therapy for patients with end-stage PBC. Cirrhotic patients with PSC also benefit from OLT, with an outcome comparable to that of liver cirrhosis of other etiologies.

Entities:  

Mesh:

Year:  2005        PMID: 15879622     DOI: 10.1385/CRIAI:28:2:167

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  31 in total

1.  Duct-to-duct biliary anastomosis for patients with sclerosing cholangitis undergoing liver transplantation.

Authors:  T G Heffron; G A Smallwood; T Ramcharan; L Davis; K Connor; E Martinez; A C Stieber
Journal:  Transplant Proc       Date:  2003-12       Impact factor: 1.066

Review 2.  Liver transplantation for primary biliary cirrhosis.

Authors:  James Neuberger
Journal:  Autoimmun Rev       Date:  2003-01       Impact factor: 9.754

3.  A prognostic model for the outcome of liver transplantation in patients with cholestatic liver disease.

Authors:  P Ricci; T M Therneau; M Malinchoc; J T Benson; J L Petz; G B Klintmalm; J S Crippin; R H Wiesner; J L Steers; J Rakela; T E Starzl; E R Dickson
Journal:  Hepatology       Date:  1997-03       Impact factor: 17.425

4.  Pretransplant prediction of prognosis after liver transplantation in primary sclerosing cholangitis using a Cox regression model.

Authors:  J Neuberger; B Gunson; P Komolmit; M H Davies; E Christensen
Journal:  Hepatology       Date:  1999-05       Impact factor: 17.425

5.  Outcome following liver transplantation for primary sclerosing cholangitis in the Nordic countries.

Authors:  B Brandsaeter; S Friman; U Broomé; H Isoniemi; M Olausson; L Bäckman; B Hansen; E Schrumpf; A Oksanen; B G Ericzon; K Höckerstedt; H Mäkisalo; P Kirkegaard; K Bjøro
Journal:  Scand J Gastroenterol       Date:  2003-11       Impact factor: 2.423

6.  Optimal timing of liver transplantation for primary biliary cirrhosis.

Authors:  W R Kim; R H Wiesner; T M Therneau; J J Poterucha; M K Porayko; R W Evans; G B Klintmalm; J S Crippin; R A Krom; E R Dickson
Journal:  Hepatology       Date:  1998-07       Impact factor: 17.425

7.  Liver transplantation for primary sclerosing cholangitis.

Authors:  E Solano; A Khakhar; M Bloch; D Quan; V McAlister; C Ghent; W Wall; P Marotta
Journal:  Transplant Proc       Date:  2003-11       Impact factor: 1.066

8.  Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry.

Authors:  René Adam; Paul McMaster; John G O'Grady; Denis Castaing; Jurgen L Klempnauer; Neville Jamieson; Peter Neuhaus; Jan Lerut; Mauro Salizzoni; Stephen Pollard; Ferdinand Muhlbacher; Xavier Rogiers; Juan Carlos Garcia Valdecasas; Joaquin Berenguer; Daniel Jaeck; Enrique Moreno Gonzalez
Journal:  Liver Transpl       Date:  2003-12       Impact factor: 5.799

9.  Midterm cost-effectiveness of the liver transplantation program of England and Wales for three disease groups.

Authors:  Louise Longworth; Tracey Young; Martin J Buxton; Julie Ratcliffe; James Neuberger; Andrew Burroughs; Stirling Bryan
Journal:  Liver Transpl       Date:  2003-12       Impact factor: 5.799

10.  Use of prognostic models for assessment of value of liver transplantation in primary biliary cirrhosis.

Authors:  G J Bonsel; I J Klompmaker; F van't Veer; J D Habbema; M J Slooff
Journal:  Lancet       Date:  1990-03-03       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.